REACH SVS Control Patient Cross-Over Study

NCT02914340 | Completed

• 1 other identifier: CPR-04524
• Study Type: interventional
• Target: 9
• Locations: 1 country
• Sites: 1

Brief Summary

This is a multicenter, prospective study designed to evaluate performance of the SVS in the REACH SVS control patients. The study is expected to enroll up to 20 patients at up to 12 sites with up to 6 patients per site.

Conditions

Emphysema

Outcome Measures

Primary Outcomes (1)

• Forced expiratory volume at 1 second

  Three months

Study Arms (1)

Treatment

EXPERIMENTAL

The treatment algorithm is complete occlusion of one lobe of the lung by using valves to occlude all segments of the lobe. The lobe will be selected based on imaging with high resolution computed tomography (HRCT). The lobe to be treated will have severe heterogeneous emphysema based on visual exam. The selected lobe will also have an intact fissure separation with the ipsilateral lobe. An intact fissure will be estimated visually to be ≥ 90% complete after viewing the HRCT in 3 dimensions. If more than one lobe meets criteria, the investigator will determine a primary lobe to treat based on fissure completeness, heterogeneity, disease severity, and the anatomy of the airways that will be treated.

Device: Spiration Valve System

Interventions

Spiration Valve System DEVICE

Treatment

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Patient was enrolled in the REACH SVS Study control group and has completed their participation in the Study including the 12 month follow-up visit.
• Patient has received standard-of-care medical management and it has been stable for 6 weeks.
• Patient is willing to participate in a study, complete the required follow-up visits, and maintain consistent nutrition and exercise habits during the study period.

You may not qualify if:

• Patient is classified as ASA Class greater than P4 including presence of co-morbidity that could significantly increase the risk of a bronchoscopy procedure.
• Patient participated in a study of an investigational drug or device within the past 30 days prior to participation in this study.
• Patient has demonstrated unwillingness or inability to complete baseline data collection procedures.
• Patient has co-existing major medical disease that will limit evaluation, participation, or follow-up in the study.
• Patient is unable to provide informed consent.
• Patient is not an appropriate candidate for or is unable to tolerate, flexible bronchoscopy procedures.
• Patient has history of 4 or more hospitalizations for COPD exacerbation or respiratory infections in the past year and none have occurred in the prior 3 months.
• Patient has evidence of systemic disease or neoplasia expected to compromise survival during the 3-month study period
• Patient has demonstrated unwillingness or inability to complete screening or baseline data collection procedures.

Sponsors & Collaborators

• Olympus Corporation of the Americas: lead

Study Sites (1)

The First Affiliated Hospital of Guangzhou Medical College

Guangzhou, Guangdong, China

Location

MeSH Terms

Conditions

Emphysema

Condition Hierarchy (Ancestors)

Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 22, 2016
• First Posted: September 26, 2016
• Study Start: September 1, 2016
• Primary Completion: June 1, 2017
• Study Completion: September 1, 2018
• Last Updated: October 24, 2018

Record last verified: 2018-10

Locations

CN (1)